, antihyperglyceamic (Ovais et al., 2013) , antihepatotoxic (Khalilullah et al., 2011) , antioxidant (Isloor et al., 2013) , angiotensin converting enzyme inhibitory (Bonesi et al., 2010) , momoamine oxidase inhibitors (Mathew et al., 2013) and anticancer activity (Bashir et al., 2011; Hayat et al., 2010; Wang et al., 2013; Havrylyuk et al., 2009; Johnson et al., 2007; Khalil et al., 2013; Havrylyuk et al., 2011; Shaharyar et al., 2010; Sharma et al., 2014) .
We planned to synthesise a series of new 5-substituted aryl-2pyrazoline derivatives and these compounds have been characterised by spectroscopic data. These compounds have been used to evaluate their in vitro anticancer activity against MCF-7 cell line by 3-(4, 5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay method and in vivo anticancer activity against EAC cell on mice model. These compounds have been optimised by Density functional theory (DFT) computation and these stimulates have been used for molecular docking evaluation to support the mechanism of anticancer action.
Materials and methods
All the chemicals used in this study were procured from Spectrochem Pvt. Ltd., Mumbai, Merck specialties Pvt. Ltd., Mumbai, and S.D. Fine Chem. Ltd., Mumbai, without further purification. The compounds (5a-f) were synthesized by reported method (Choudhary et al., 2011) . The melting points were determined by open capillary method using Veego melting point apparatus (VMP-DS) and were uncorrected. The purity of compounds was checked by thin layer chromatography (TLC) on silica gel-G plate of 0.5 mm and developed plates were visualized by iodine vapour or UV light. Fourier transform Infrared (FT-IR) spectra were recorded on a Bruker FTIR -1 1 13 ALPHA in the range 4000-400 cm . H NMR and C NMR TM spectra were recorded on a Bruker Ultra shield 300 MHz spectrometer using Deuterated chloroform (CDCl ) as solvent 3 and Tetramethylsylsilane (TMS) as internal standard (chemical shifts in δ ppm). Splitting patterns was designated as s (singlet), d (doublet), t (triplet), q (quart) and m (multiplet). Mass spectra were recorded on a G2 QTOF XEVO mass spectrometer. UV was measured by multimode plate reader Spectra Max M5; Molecular Devices. Elemental analysis was recorded on Perkin Elmer 2400 series II.
Procedure for the synthesis of 3-(substituted aryl)-1-(4methoxyphenyl)-prop-2-en-1-one (3a-f)
A mixture of 4-methoxyacetopheone (0.01 mol) 1 and aromatic aldehyde (0.01 mole) 2 was dissolved in 10 ml ethanol in a 250 ml of round-bottom flask fitted with a magnetic stirrer. After 30 minutes 10 ml of sodium hydroxide solution (10%) was added drop wise into the reaction mixture. Then solution becomes turbid and the reaction mixture was maintained between 10-0 15 C by using ice water batch. After vigorous stirring for 5-6 hr the mixture was neutralized by adding 0.1-0.2N HCl where the precipitation occurred. Then precipitate was collected by filtration, dried and recrystallized from ethanol/ethyl acetate to get corresponding 3-(substituted aryl)-1-(4-methoxyphenyl)-prop-2-en-1-one (3a-f) (Choudhary et al., 2011) .
Procedure for the synthesis of 5-substituted aryl-2pyrazoline derivatives (5a-f)
These 3-(substituted aryl)-1-(4-methoxyphenyl)-prop-2en-1-one (0.01 mole) 3a-f and 2, 4-dinitrophenyl hydrazine (0.01 mole) 4 was dissolved in 20 ml of glacial acetic acid in a 250 ml of round bottom flask. Then reaction mixture was refluxed for 12-14 hrs. The completion of the reaction was monitored by TLC. After completion of the reaction the product was poured in crushed ice and allowed to stand overnight. The precipitate was collected by filtration, dried and recrystallized from water: methanol/ethanol, ethyl acetate to get desired 5-substituted aryl-2-pyrazoline derivatives (5a-f) ( . In vitro MTT antiproliferative assay 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) method was used to determine the effects of 5-substituted aryl-2-pyrazoline derivatives (5a-f) on cell proliferation in the MCF-7 cell line. MCF-7 cells were cultured in (DMEM) Dulbecco's modified Eagle's medium without phenol red and supplemented with 10% fetal bovine serum. The cell culture medium was maintained at 37°C in a humidified incubator containing 5% CO 2 atmosphere. To evaluate the cell cytotoxicity/viability, the 3 cells were evenly distributed at a density of 5×10 cells/well (optimal seeding density) in 96 well plates and it was incubated at 37°C in 5% CO incubator (Model MCO-2 15AC; Sanyo Electric Biomedical Co. Ltd., Osaka, Japan) overnight. Then the medium in the wells was replaced by fresh medium with or without 5-substituted aryl-2pyrazoline derivatives (5a-f) as well as standard drug 5-Fluorouracil (5-FU) with varying concentrations and incubated for 48 hours. Subsequently, the medium in each www.ajpp.in well was replaced with 20 µl MTT (5mg/ml in PBS) and the incubation was continued for 4 hours. The medium in each well containing unbound MTT and death cells was removed by suction. The purple-blue formazan precipitate was dissolved in 100 µl dimethylsulfoxide and the absorbance of each well was measured at a wavelength of 570 nm on a Microplate reader (Multimode plate reader, Spectra Max M5; Molecular Devices, CA, USA). All the experiments were performed in triplicate. The IC was calculated as the concentration of compounds that 50 achieved a 50% inhibition of cell viability. The percentage cell viability of the compound was calculated by:
1-(2, 4-dinitrophenyl)-3, 5-bis-(4-methoxyphenyl)-2pyrazoline (5a)
In vivo anticancer activity All tested compounds (5a-f) were administered at dose of 400 mg/kg, did not show any gross behavioural change or mortality up to 24 hr. Swiss albino mice of 10 weeks old with an average body weight 20 to 25 gm were used in this experiment. All mice were kept in good laboratory conditions supplied basal diet after dividing into nine groups (n=12). All methodology related to animal experiment were assessed and permitted by the University Animals Ethical Committee (Registration No: AEC/PHARMA/1501/08/2015), Jadavpur University, India. EAC cells were collected from Chittaranjan National Cancer Institute, Kolkata and suspended in sterile isotonic solution (0.9% w/v NaCl). The numbers of tumour cells per ml of this suspension were measured under microscope by using haemocytometer. All these groups of animals were injected with 6 EAC cell (2 x 10 cell/mice) intraperitoneally except the normal control group (I). This was taken as zero days. Animals were allowed for 24 hr inoculation for the cancer to grow in the body st before starting the drug administration. On 1 day 5 ml/kg, body weight of normal saline (0.9% w/v NaCl) was administered in normal control groups (I) as well as EAC control groups (II). After inoculation the synthesized compounds (5a-f) (400 mg/kg body weight/day) was given orally (III-VIII) and the standard drug 5-FU (20 mg/kg body weight/day) intraperitoneally were th administered in groups (IX) for 7 days respectively. On the 9 day food and water were withheld 18 hr before start of dissection of animals. The weights of animals were recorded before and after sacrifice. Then blood was collected from heart; ascites fluids were collected from peritoneal cavity and liver was taken for histopathology study. Remaining animals were kept for observing mean survivable time .
The anticancer activities of the compounds were measured in EAC animals with respect to the following parameters such as: tumour weight, viable and non viable tumour cell counts were measured according to Ghosh et al. (2011) and Dash et al. (2010) . The haematological parameter like haemoglobin (HB), red blood cells (RBC), white blood cells (WBC), Serum glutamic oxaloacetate transaminase (SGOT), Serum glutamic pyruvate transaminase (SGPT), bilirubin, total protein and creatinine were measured according to Ghosh et al. (2011) .
The mean survival time (MST) of treated animals was calculated by using the formula:
The percentage increases in the life span (% ILS) was calculated by using the formula:
The MST and % ILS was calculated according to Bala et al. (2010) .
Statistical analysis
All Statistical results were calculated by using Graph Pad Prism software. The values were recorded as mean ± standard error mean (SEM). The data were analyzed by using Analysis of variance (ANOVA); deference below the 0.001 level (p<0.05) were considered as statistically significant.
DFT and Docking studies
Geometry optimization of all the compounds was performed by DFT/B3LYP method using Gaussian 09 software (Becke 1993; Lee 1988 ). 6-311G+ (d,p) basis set were used for C, H, N, O. The vibrational frequency calculations were performed to ensure that the optimized geometries represent the local minima and there are only positive eigenvalues. Theoretical UV-Vis spectra were calculated by time-dependent-DFT/B3LYP method in methanol using conductor-like polarizable continuum model (CPCM) was used to calculate the fractional contributions of various groups to each molecular orbital (Barone et al., 1998; Cossi et al., 2001; Cossi et al., 2003; O'Boyle et al., 2008) .
Molecular docking studies allow to predict the best interaction of small molecules (ligands) with proteins (enzyme) (Kirkpatrick 2004 ). In the present work, docking study was performed using the CDOCKER protocol in Discovery Studio 3.5 (Ojha and Roy, 2010) . (Discovery Studio 3.5, Accelrys, Inc. San Diego, CA) in order to identify the interaction between compounds and EGFR or Human epidermal growth factor receptor-2 (HER-2) as well as to visualize the probable binding mode. Docking study has been conducted for all synthetic compounds into the active site of the receptor EGFR and HER-2. The crystal structures of EGFR (PDB code: 1M17) complex were retrieved from the RCSB Protein Data Bank www.ajpp.in (http://www.rcsb.org/pdb). The site sphere was selected based on the ligand binding location after preparing the receptor and ligand. Ligand preparation was done by using Prepare Ligand module in Receptor-Ligand interactions tool of Discovery studio 3.5. Energy minimized ligand structure of the compounds were used for docking. Protein preparation was also done under Prepare Protein module of Receptor-Ligand interactions tool of Discovery Studio 3.5. The prepared protein was considered as receptor and active site was selected based on the ligand binding domain of the compounds, the pre-existing ligand was removed and prepared ligand was placed. Most favorable docked pose was selected based on the minimum free energy of proteinligand complex and analyzed to investigate the interaction.
ADMET prediction
Adsorption, distribution, metabolism, excretion and toxicity (ADMET) is under descriptor module of small molecules protocol of Discovery studio client 3.5. Drug likeness of a compound could be checked following Lipniski's rule of five (Lipinski et al., 2001) .
Results and discussion
In the present study a new series of 5-substituted aryl-2pyrazoline derivatives (5a-f) have been synthesized by the synthetic route outlined in figure 1. The synthesized compounds hydrogen show triplet at 6.99-9.00 ppm was formed. C NMR spectra of all compounds have shown that aliphatic-Cs resonate at 76-77 ppm while aromatic-Cs appear at 120-140 ppm. The composition of the compounds has been supported by mass spectroscopy and elemental analysis.
All the synthesized compounds (5a-f) have been evaluated for in vitro cytotoxic activity against MCF-7 cell line by MTT assay method. The results are summarized in table 1. Screening results of in vitro anticancer study (Table 1) revealed that the compound 1-(2,4-dinitrophenyl)-5-(4chlorophenyl)-3-(4-methoxyphenyl)-2-pyrazoline (5c) (IC =2.42 ±0.26 mg/l) and compound 1-(2,4-dinitrophenyl)- (Table 1) it is recommended that the compounds 5c and 5e have shown > 50% inhibition at a concentration of 100 µl/ml which is preferred for their in vitro anticancer activity against MCF-7 cell line by using MTT assay method.
In the present study, all these synthesized compounds (5a-f) were evaluated for in vivo cytotoxic activity against EAC cell bearing mice model in Table-2 and Screening results of in vivo anticancer study suggest that, compound 5b and 5f showed tumour weight inhibition (50.13%) and (47.39%) with respect to control 5-FU (74.90%). However, the viable and non viable tumour cell count of compound 5c have shown most significant (p<0.01) as compared to EAC control group. Moreover, in figure 2 it is revealed that the count of red blood cells and haemoglobin of compound 5a and 5c have shown gradually increased (p<0.05) as compared to EAC control group. In addition, the WBC cells count of all drug treated groups have shown gradually decreased (p<0.05) with respect to EAC control group.
Furthermore, in (Table 3) and SGOT level of all drug treated compounds exhibited significant difference (p<0.01) as compared to EAC control group. However, bilirubin levels of compound 5b and 5f have shown significant (p<0.01) decrease with respect to EAC control group. Whereas, the total protein level of drugs 5b and 5f treated groups have shown slight increase in level with respect to the EAC control group. In the table 4 reveals that compounds 5b and 5f shown mean survival time was 34 and 30 day respectably. In other hands the percentage of ILS estimation of compounds 5b and 5f shown to be 70% and 75% as compared to control 5-FU was 145%.
DFT computation and in-silico Docking study
The Density Functional Theory (DFT) computation has been used to generate stable optimised geometry (Figure 3) of the drugs and to calculate their population of molecular functions and energy. These data have been used to interpret the solution spectral properties and drug likeness feature as well as drug efficiency. The energy difference between HOMO (highest occupied molecular orbital) and LUMO (lowest unoccupied molecular orbital) functions refer to intramolecular charge transfer transitions that is supported by electronic spectral data. Crystallographic structure of EGFR is downloaded from RCSB protein data bank (PDB ID: 1M17) which was resolved at 2.60Å in X-Ray diffraction. Energy minimized structure of compounds (5af) are used for in silico protein ligand docking studies in the www.ajpp.in 
Drug likeness and ADMET prediction
Drug likeness of all the ligands were checked following Lipniski's rule of five. ADMET modules of discovery studio were used to check ADMET (absorption, distribution, metabolism, excretion and toxicity) property of the compounds. Toxicity prediction, Aqueous solubility, Blood Brain barrier penetration, Human Intestinal Absorption, Ames mutagenicity was predicted under the Calculate Molecular Property module of Small molecule tool of Discovery Studio client 3.5. Predicted data were summarized in table 5.
Conclusion
In summary, 5-substituted aryl-2-pyrazoline derivatives have been synthesized and structurally established by different spectral data. Their anticancer activities against MCF-7 cell lines and EAC cells have been evaluated. The results revealed that compound 1-(2, 4-dinitrophenyl)-5-(4-chlorophenyl)-3-(4methoxyphenyl)-2-pyrazoline (5c) with IC (2.42 ±0.26mg/l) 50 and 1-(2,4-dinitrophenyl)-5-(4-N,N-dimetyl amino phenyl)-3-(4-methoxyphenyl) -2-pyrazoline (5e) with IC (2.75 ± 0.33 50 mg/l) exhibit significant anticancer activity against MCF-7 cell lines superior to 5-FU. However 1-(2, 4-dinitrophenyl)-5-(2chlorophenyl)-3-(4-methoxyphenyl)-2-pyrazoline (5b) and 1-(2,4-dinitrophenyl)-5-(3-nitrophenyl)-3-(4-methoxyphenyl)-2pyrazoline (5f) exhibited the significant anticancer activity against EAC cells bearing mice model. Moreover we found compound 1-(2, 4-dinitrophenyl)-5-(4-chlorophenyl)-3-(4-methoxyphenyl)-2-pyrazoline (5c) and 1-(2, 4dinitrophenyl)-5-(4-N, N-dimetyl amino phenyl)-3-(4methoxyphenyl)-2-pyrazoline (5e) having the best interaction with the protein molecules and in vitro study also found that compound 1-(2, 4-dinitrophenyl) -5-(4chlorophenyl)-3-(4-methoxyphenyl)-2-pyrazoline (5c) and compound 1-(2,4-dinitrophenyl)-5-(4-N, N-dimetyl amino phenyl)-3-(4-methoxyphenyl)-2-pyrazoline (5e) have potent cytotoxicity. Hence compound 1-(2, 4dinitrophenyl)-5-(4-chlorophenyl)-3-(4-methoxyphenyl)-2-pyrazoline (5c) and compound 1-(2, 4-dinitrophenyl)-5-(4-N, N-dimetyl amino phenyl)-3-(4-methoxyphenyl)-2pyrazoline (5e) could be considered as bioactive molecules for future development and research and hope to get more target specific, less toxic and potent anticancer activity. # 0, Extremely low; 1, very low but possible; 2, yes low; 3, yes, good; 4, yes, optimal; 5, no, too soluble. 
